Saluda Medical Successfully Completes First U.S. Surgeries Using CAP24™ Paddle Lead Technology

Saluda Medical Breakthrough: First U.S. Surgeries with CAP24™ Paddle Lead

Saluda Medical, a pioneering company in the medical device sector, has made headlines after successfully completing the inaugural surgeries in the U.S. utilizing its revolutionary CAP24™ paddle lead technology. This important event, heralded as a significant advancement in closed-loop neuromodulation for chronic neurological conditions, reflects the company's commitment to improving patient care through innovative medical solutions.

On July 10, Dr. Erika A. Petersen, a respected Professor of Neurosurgery at the University of Arkansas for Medical Sciences (UAMS), performed the very first cases with this new Paddle Lead. Just a few days later, on July 14, Dr. Steven M. Falowski, the Director of Functional Neurosurgery at Advanced Surgery Center of Lancaster in Pennsylvania, also contributed to this historic moment, expanding the reach of the Evoke® physiologic closed-loop therapy in surgical settings across the United States.

The CAP24™ paddle lead represents a groundbreaking shift in how neuromodulation can be applied during surgical procedures. Historically, paddle leads have been favored by many within the neurosurgery and orthopedic spine surgery community, accounting for approximately 30% of spinal cord stimulator (SCS) implants in the U.S. By integrating the Evoke Therapy into these surgeries, Saluda Medical is opening up new possibilities for patients who are in need of effective pain management interventions.

In a statement regarding the procedure, Dr. Petersen noted, "These first CAP24™ cases are an exciting advance for closed-loop therapy. Bringing Evoke®'s physiologic, ECAP‑based neuromodulation into paddle procedures gives patients more consistent, objective therapy." This type of therapy's physiological feedback allows for real-time adjustments based on each patient’s neural signal, offering a personalized treatment experience that can lead to improved outcomes.

Adding to this sentiment, Dr. Falowski expressed, "Being able to deliver closed-loop therapy in a paddle procedure changes what we can offer surgical patients. CAP24™ brings Evoke®'s real-time, physiology-based approach into the operating room, which is an important evolution for SCS." The ability to adaptively enhance therapy during surgery signifies a major step forward in surgical patient care.

Mike Mathias, the Chief Commercial Officer of Saluda Medical, also highlighted the importance of this milestone, stating, "These first U.S. surgical cases are an important milestone for Saluda and for patients. CAP24™ opens the surgical channel for closed-loop therapy and brings Evoke™ Therapy to more people who need it." By broadening the application of this advanced therapy, the company is poised to positively impact many lives through effective pain management strategies.

The CAP24™ is noteworthy for being the first SCS paddle lead purposefully designed for closed-loop neuromodulation. Unlike traditional methods, it is engineered to accurately sense each patient's unique neural signals and deliver precise therapy accordingly. Backed by extensive clinical evidence demonstrating its effectiveness, Evoke® Therapy has proven to provide sustainable pain relief over a duration of 36 months. This scientific foundation empowers Saluda Medical with the confidence to advance their technology into new clinical arenas.

Although the implementation of this innovative technology is just beginning in the U.S., its introduction in surgeries marks an exciting period in the treatment of chronic pain and neurological conditions. As Saluda Medical continues to develop and distribute their products, they remain committed to transforming how chronic pain is managed.

In conclusion, the launch of the CAP24™ paddle lead technology represents a remarkable leap toward better, more personalized treatment for patients suffering from chronic pain conditions. With its capabilities, Saluda Medical is set to redefine the field of neuromodulation and provide hope to countless individuals seeking relief from their distressing symptoms.